Biopharma Daily Stock Updates - 02/22/21

$XBI $154.29 -3% 📉

Covid Updates

$NVAX -12% Enrollment complete in pivotal ph 3 trial in US and Mexico. source

Pipeline Updates

$CYDY -19% Unblinded ph 2/3 data for the CD12 Covid-19 trial but is talking with regulatory agencies before releasing the data and meeting details. source

$OTIC -44% Ph 3 trial of OTIVIDEX for Ménière's disease failed. Company will turn focus to other assets in pipeline. source

$SUPN -1% Received notice from the U.S. Food and Drug Administration (FDA) that the company’s New Drug Application (NDA) resubmission for SPN-812 for the treatment of ADHD in pediatric patients is considered a Class I resubmission thereby assigning a timeline of two months for review by the FDA and establishing a new Prescription Drug User Fee Act (PDUFA) target action date in early April 2021. source

$SAVA -5% Alignment with FDA on two registrational phase 3 trials to be initiated in H2 2021. source

$RVNC -4% Mixed-positive phase 2 data released. company plans to conduct an end-of-phase-2 meeting with FDA prior to initiating phase 3 program. source

Financial Updates

$ARCT -11% acquires exclusive license to mRNA manufacturing technology from Alexion Pharma. source


*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Big Movers™ is a trademark of Amp Biotech Research, LLC

©2021 by Biopharm IQ. Website by Awaken Studio.